A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Giannakakis, T. | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Onienaoum, A. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Andreopoulou, E. | en |
dc.contributor.author | Bamia, C. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Giannakakis, T. | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Onienaoum, A. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Andreopoulou, E. | en |
dc.creator | Bamia, C. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.date.accessioned | 2018-06-22T09:53:04Z | |
dc.date.available | 2018-06-22T09:53:04Z | |
dc.date.issued | 1997 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41639 | |
dc.description.abstract | Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April 1996, 167 patients with ABC were randomized to receive epirubicin (110 mg/m2) either every four (81 patients, group A) or every two weeks (86 patients, group B). Filgrastim (5 μg/kg/daily) was administered prophylactically on days 2-12 of each cycle. Results: The two groups were equally balanced in terms of major patient and tumor characteristics. Even though the median cumulative close of epirubicin was identical in the two groups (651 mg/m2), the median DI of epirubicin was doubled in group B (27.2 vs. 52.9 mg/m2/wk, respectively). The complete response (CR) rate was significantly increased in group B (5%, 95% CI: 0.16%-9.84% vs. 17%, 95% CI: 8.9%-25.08%, P = 0.011), although overall response rates were similar (49% vs. 53%, P = 0.5957). Also, there was no significant difference in the incidence of grade 3-4 toxicity between the two groups. After a median follow-up of 25 months (range, 0.43-43.3+) no significant difference was observed in the duration of response (median, 10 months vs. 8.5 months, P = 0.5130), time to progression (median, 7.2 months vs. 7.4 months, P = 0.2970) or survival (median, 14.6 months vs. 14.9 months, P = 0.4483). Logistic regression analysis showed that performance status was a significant variable for response (P = 0.0068) and multivariate analysis using the Cox proportional hazards model revealed that performance status was significant for survival (P = 0.0049), while the presence of multiple metastases (P = 0.0020) was significant for time to progression. Conclusion: Doubling the planned DI of epirubicin monotherapy significantly increases the CR rate but has no influence on time to progression or survival in patients with ABC. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast cancer | en |
dc.subject | Controlled study | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Drug response | en |
dc.subject | Priority journal | en |
dc.subject | Clinical trial | en |
dc.subject | Disease-free survival | en |
dc.subject | Treatment outcome | en |
dc.subject | Survival analysis | en |
dc.subject | Drug administration schedule | en |
dc.subject | Metastasis | en |
dc.subject | Dose response | en |
dc.subject | Male | en |
dc.subject | Antineoplastic | en |
dc.subject | Epirubicin | en |
dc.subject | Breast neoplasms | en |
dc.subject | Antibiotics | en |
dc.title | A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1023/A:1008270307264 | |
dc.description.volume | 8 | |
dc.description.issue | 12 | |
dc.description.startingpage | 1213 | |
dc.description.endingpage | 1220 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961|0000-0002-6801-3129 | |
dc.gnosis.orcid | 0000-0002-3286-778X |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |